Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
HTC-867
- Development stage
- Phase 1
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
HTC-867 is a small molecule investigational drug that has undergone early-phase clinical evaluation. A Phase 1 study was conducted to assess the safety, tolerability, and pharmacokinetics of ascending single oral doses of HTC-867 in healthy young and elderly subjects. The study also evaluated how the drug is absorbed, distributed, metabolized, and excreted under both fasted and fed conditions. The specific mechanism of action or therapeutic target for HTC-867 has not been disclosed in publicly available sources. Its chemical class is described as an organic heterocyclic compound.
- Other names
- 6-Wyeth is now a wholly owned subsidiary of Pfizer-cognitive impairment associated with schizophrenia
02
Targets
HTR6 (5-hydroxytryptamine receptor 6)
Beyond the preview
Go deeper on HTC-867.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on HTC-867.